New imaging agent could help spot tumors in future cancer trials

NCT ID NCT01269593

Ongoing Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatment study; the results will help plan future trials that use higher doses of PUH71 to treat cancer or detect tumors with PET scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 124I-PUH71 (a radioactive imaging agent)
What this could lead to: If successful, this could help doctors use PUH71 to detect tumors with PET scans and guide future treatment studies at higher doses.
What could go wrong: This is a very early pilot study with only tiny doses of the drug. It is not designed to treat cancer, and the imaging approach may not work well for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE SOLID MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lymphoma myeloproliferative neoplasm non-Hodgkin lymphoma plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACTIVE SOLID MALIGNANCY MYELOMA NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.